Efficiencies resulting from rare disease network

April 2007
Clinical Trials Administrator;Apr2007, Vol. 5 Issue 4, p40
The article focuses on challenges faced by the Rare Diseases Clinical Research Network (RDCRN) of the U.S. National Institutes of Health. According to the author, some researchers were able to turn the disadavantages into assets for the investigation. Richard J. Barohn of the nondystrophic myotonias consortium, said that they used an interactive voice response call-in system in their investigation to collect data on the symptoms of the patients.


Related Articles

  • It's All about Patients. Bergstresser, Paul R. // Journal of Investigative Dermatology;Jan2010, Vol. 130 Issue 1, p1 

    The author reflects on the significance of patients in research studies as well as the impact of their disease in the U.S. He mentions that the patient advocate organizations are guided with the goals and mission of the National Institute of Health (NIH) . He notes that the target of funding and...

  • NIH grant creates opportunities and supports new trial practices.  // Clinical Trials Administrator;Apr2007, Vol. 5 Issue 4, p37 

    The article reports on the funding provided by the U.S. National Institutes of Health (NIH) for the investigation of diseases in the U.S. A $71 million funding was provided by NIH to the Rare Diseases Clinical Research Network to investigate rare diseases, such as lung disease, thrombotic...

  • Research, treatment benefit from NIH grant and network.  // Clinical Trials Administrator;Apr2007, Vol. 5 Issue 4, p41 

    The article discusses how the Rett syndrome research within the Rare Diseases Clinical Research Network (RDCRN) provided treatment benefits. According to the article, the research that was funded by the U.S. National Institutes of Health provided greater understanding of the disease process and...

  • Teams will use latest tools to investigate undiagnosed diseases. Roehr, Bob // BMJ: British Medical Journal (International Edition);5/24/2008, Vol. 336 Issue 7654, p1149 

    The article reports on a unique program which has been developed by the U.S. National Institutes of Health. The program, which will offer the latest advances in tools and medical information, will allow patients who have signs and symptoms that doctors have not been able to give a diagnosis for,...

  • Global Rare Diseases Patient Registry and Data Repository (GRDR) Notice and Request for Information (RFI). Insel, Thomas // Federal Register (National Archives & Records Service, Office of;2/10/2012, Vol. 77 Issue 28, p7167 

    The article reports that the U.S. Office of Rare Diseases Research (ORDR) of the U.S. National Institutes of Health's National Center for Advancing Translational Sciences is intended to conduct a two-year pilot project to establish the Global Rare Diseases Patient Registry and Data Repository...

  • NIAMS Study to Determine How Patients Evaluate Improvements In RA Symptoms.  // PT: Magazine of Physical Therapy;Oct2004, Vol. 12 Issue 10, p72 

    Presents a clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms, conducted by the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health. Terms of the clinical study; Evaluation of...

  • My days as a policy wonk. Santoro, Nanette F. // Contemporary OB/GYN;Jun2005, Vol. 50 Issue 6, p112 

    Presents an article regarding the participation of a physician in a consensus panel of the U.S. National Institute of Health to evaluate the evidence on menopause symptomatology. Impact of menopausal transition on women; Qualities of research on treatment for symptoms of menopause demanded by...

  • National Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related Symptoms.  // Annals of Internal Medicine;6/21/2005, Vol. 142 Issue 12, p1003 

    National Institutes of Health (NIH) consensus and state- of-the-science statements are prepared by independent panels of health professionals and public representatives on the basis of 1) the results ofa systematic literature review prepared under contract with the Agency for Healthcare Research...

  • Rare Diseases Get $187M From European Commission. Moran, Nuala // BioWorld Today;3/ 7/2013, Vol. 24 Issue 44, p1 

    The article reports on the move of the European Commission (EC) to grant $187 million to several projects that find treatments for 200 diseases by 2020. The projects will bring together more than 300 participants from 29 countries across Europe and the U.S. and will cover diseases ranging from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics